Company: VCYT
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001384101-25-000110
Chunk: 34

Company: VERACYTE, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
 used in assessing performance of the Company's single segment, allocating resources and in establishing management’s compensation. The Company's chief operating decision maker intends for all revenue generating activities to rely on cross-functional activities across the consolidated entity in order to operate. No individual besides the chief operating decision maker has been tasked with reviewing discreet operating results of the business activities, nor is there any intent to bifurcate the overall business review process to produce discreet operating results specific to any of the Company's business activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Consolidated revenue does not include any inter-segment sales or transfers.

17

Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):Three Months Ended June 30,Six Months Ended June 30,2025202420252024Revenue:Testing revenue$122,263 $106,970 $229,572 $197,273 Product revenue3,598 3,906 7,178 7,443 Biopharmaceutical and other revenue4,303 3,552 7,887 6,556 Total revenue130,164 114,428 244,637 211,272 Cost of revenue:Cost of testing revenue:Laboratory supplies and reagents expense15,304 13,326 28,369 25,244 Sample collection expense3,494 3,164 6,320 6,221 Compensation expense6,023 5,139 11,634 10,354 Other cost of testing revenue (1)4,173 3,479 7,559 6,325 Allocation of facilities and IT expenses3,413 2,812 6,785 5,755 Total cost of testing revenue32,407 27,920 60,667 53,899 Cost of product revenue:Product costs705 628 813 1,891 License fees and royalties307 314 631 751 Other cost of product revenue (2)515 800 1,309 1,623 Allocation of facilities and IT expenses222 132 418 253 Total cost of product revenue1,749 1,874 3,171 4,518 Cost of biopharmaceutical and other revenue:Compensation expense1,652 2,072 2,892 3,533